<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416559</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454574</org_study_id>
    <secondary_id>CCLG-NB-1995-06</secondary_id>
    <secondary_id>EU-20596</secondary_id>
    <secondary_id>CCLG-94-01</secondary_id>
    <nct_id>NCT00416559</nct_id>
  </id_info>
  <brief_title>Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only</brief_title>
  <official_title>Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A &amp; 2B Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Observation is closely monitoring a patient's condition and not giving treatment&#xD;
      until symptoms appear or change. Observation may help doctors see how effective surgery is in&#xD;
      treating neuroblastoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well surgery alone works in treating young&#xD;
      patients with localized neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the safety and efficacy of surgical treatment alone in young patients with&#xD;
           stage 2 neuroblastoma without N-myc amplification (NMA).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine predictive factors of relapse and survival of patients with stage 1, 2A, or 2B&#xD;
           neuroblastoma without NMA who have undergone surgery only.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter study.&#xD;
&#xD;
      Patients with stage 1 or 2 disease and no N-myc amplification (NMA) undergo observation&#xD;
      comprising clinical evaluation, ultrasound or CT scan of the abdomen, and chest x-ray&#xD;
      periodically for up to 5 years. All other patients undergo additional therapy and follow-up&#xD;
      according to national standards. Patients who develop recurrent disease or disease&#xD;
      progression may undergo surgical resection, preceded or followed by chemotherapy, according&#xD;
      to national standards.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of relapse and survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Long-term Effects Secondary to Cancer Therapy in Children</condition>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical observation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed neuroblastoma or ganglioneuroblastoma&#xD;
&#xD;
          -  Meets 1 of the following International Neuroblastoma Staging System (INSS) criteria:&#xD;
&#xD;
               -  Stage 1&#xD;
&#xD;
               -  Stage 2A or 2B meeting 1 of the following criteria:&#xD;
&#xD;
                    -  With or without N-myc amplification&#xD;
&#xD;
                    -  No evaluation of NMA&#xD;
&#xD;
                    -  Symptomatic spinal cord compression&#xD;
&#xD;
               -  Stage 3*&#xD;
&#xD;
               -  Dumbbell syndrome with clinical signs of spinal cord compression*&#xD;
&#xD;
          -  NOTE: *These patients are eligible for the study but do not undergo observation;&#xD;
             instead they will undergo standard treatment&#xD;
&#xD;
          -  Has undergone complete or gross surgical resection OR diagnostic surgical or needle&#xD;
             biopsy&#xD;
&#xD;
          -  No metastases within 1 month of diagnosis&#xD;
&#xD;
               -  No skin metastases by clinical examination and MIBG scan&#xD;
&#xD;
               -  Normal liver by CT scan or ultrasonography&#xD;
&#xD;
               -  Normal chest X-ray (in case of nonthoracic primary site)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno De Bernardi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Giannina Gaslini</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Marie Michon, MD</last_name>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>long-term effects secondary to cancer therapy in children</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

